Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03899467 · ClinicalTrials.gov registry record · Phase 2
The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC
A Phase 2 study, sponsored by Suzhou Kintor Pharmaceutical Inc,.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT03899467 is a Phase 2 study that has completed, run by Suzhou Kintor Pharmaceutical Inc,. The registered enrollment target is 61 participants.
The verdict
NCT03899467, a Phase 2 study, has completed, sponsored by Suzhou Kintor Pharmaceutical Inc,.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
This was a multiple-center, open-label, randomized, daily dose, two-sequence, expanded/phase II study in subjects with mHSPC or mCRPC who progressed after either abiraterone or enzalutamide treatment. The objective of the study is to evaluate the safety and tolerability of proxalutamide and determine the RP2D for Ph III and/or other confirming studies. Subjects will be randomized into the 2 treatment arms.
Interventions
- DRUG GT0918
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2019-05-30 |
| Est. Completion | 2022-09-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03899467
The ClinicalTrials.gov registry entry for NCT03899467 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Suzhou Kintor Pharmaceutical Inc,, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GT0918 is the first listed.
NCT03899467 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03899467 about?
NCT03899467 is a clinical study titled "The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC". This was a multiple-center, open-label, randomized, daily dose, two-sequence, expanded/phase II study in subjects with mHSPC or mCRPC who progressed after either abiraterone or enzalutamide treatment. The objective of the study is to evaluate the safety and tolerability of proxalutamide and determi...
What is the current status of trial NCT03899467?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2019-05-30. Estimated completion is 2022-09-19.
What interventions are being tested in trial NCT03899467?
The interventions under investigation include: GT0918 (DRUG).
Who is sponsoring clinical trial NCT03899467?
This trial is sponsored by Suzhou Kintor Pharmaceutical Inc,, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.